Effects of FK506-binding protein 12 and FK506 on autophosphorylation of epidermal growth factor receptor - PubMed (original) (raw)
. 1998 Apr 17;273(16):9430-4.
doi: 10.1074/jbc.273.16.9430.
Affiliations
- PMID: 9545268
- DOI: 10.1074/jbc.273.16.9430
Free article
Effects of FK506-binding protein 12 and FK506 on autophosphorylation of epidermal growth factor receptor
M Lopez-Ilasaca et al. J Biol Chem. 1998.
Free article
Abstract
FK506-binding proteins and cyclophilins are intracellular proteins that express peptidylproline cis-trans-isomerase (PPIase) activity. The effects of FK506-binding protein 12 (FKBP12) and the cyclophilins 18 and 23 on autophosphorylation of the epidermal growth factor (EGF) receptor prepared from plasma membranes of the human epidermoid cell line A431 have been investigated. Whereas FKBP12 inhibited EGF receptor tyrosine kinase activity in a concentration-dependent manner, the cyclophilins did not affect autophosphorylation. In contrast to the wild-type enzyme, several variants of FKBP12 with greatly reduced PPIase activity were unable to suppress EGF receptor tyrosine kinase significantly. Pervanadate an inhibitor of protein tyrosine phosphatases, abolished the effect of FKBP12 on EGF receptor autophosphorylation. Finally, FK506 and rapamycin, which are known to block the PPIase activity of FKBP12, induced a significant stimulation of EGF receptor autophosphorylation in intact A431 cells suggesting suppression of EGF receptor autophosphorylation by intracellular FKBP12 in vivo. Taken together the data point to an inhibitory function of FKBP12 in EGF receptor signaling, possibly induced by stimulation of a protein tyrosine phosphatase coupled to the EGF receptor. Both PPIase activity and substrate specificity of FKBP12 seem to be indispensable for this effect.
Similar articles
- FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes.
DeCenzo MT, Park ST, Jarrett BP, Aldape RA, Futer O, Murcko MA, Livingston DJ. DeCenzo MT, et al. Protein Eng. 1996 Feb;9(2):173-80. doi: 10.1093/protein/9.2.173. Protein Eng. 1996. PMID: 9005438 - Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506.
Shirakata Y, Kobayashi M, Ohtsuka K, Sugano M, Terajima H, Ikai I, Okajima H, Egawa H, Inomata Y, Inamoto T, et al. Shirakata Y, et al. Transplantation. 1995 Dec 27;60(12):1582-7. doi: 10.1097/00007890-199560120-00035. Transplantation. 1995. PMID: 8545894 - Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin.
Bell A, Wernli B, Franklin RM. Bell A, et al. Biochem Pharmacol. 1994 Aug 3;48(3):495-503. doi: 10.1016/0006-2952(94)90279-8. Biochem Pharmacol. 1994. PMID: 7520696 - The chemistry of signal transduction.
Clardy J. Clardy J. Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):56-61. doi: 10.1073/pnas.92.1.56. Proc Natl Acad Sci U S A. 1995. PMID: 7529414 Free PMC article. Review. - Neural roles of immunophilins and their ligands.
Sabatini DM, Lai MM, Snyder SH. Sabatini DM, et al. Mol Neurobiol. 1997 Oct;15(2):223-39. doi: 10.1007/BF02740635. Mol Neurobiol. 1997. PMID: 9396011 Review.
Cited by
- Everolimus induces Met inactivation by disrupting the FKBP12/Met complex.
Raimondo L, D'Amato V, Servetto A, Rosa R, Marciano R, Formisano L, Di Mauro C, Orsini RC, Cascetta P, Ciciola P, De Maio AP, Di Renzo MF, Cosconati S, Bruno A, Randazzo A, Napolitano F, Montuori N, Veneziani BM, De Placido S, Bianco R. Raimondo L, et al. Oncotarget. 2016 Jun 28;7(26):40073-40084. doi: 10.18632/oncotarget.9484. Oncotarget. 2016. PMID: 27223077 Free PMC article. - Upregulated FKBP1A Suppresses Glioblastoma Cell Growth via Apoptosis Pathway.
Cai S, Chen Z, Tang H, Meng S, Tao L, Wang Q. Cai S, et al. Int J Mol Sci. 2022 Nov 29;23(23):14935. doi: 10.3390/ijms232314935. Int J Mol Sci. 2022. PMID: 36499275 Free PMC article. - The involvement of mammalian and plant FK506-binding proteins (FKBPs) in development.
Breiman A, Camus I. Breiman A, et al. Transgenic Res. 2002 Aug;11(4):321-35. doi: 10.1023/a:1016331814412. Transgenic Res. 2002. PMID: 12212836 Review. - GPCR-mediated EGFR transactivation ameliorates skin toxicities induced by afatinib.
Chen LY, You Q, Lv DZ, Li SH, Zhang SY. Chen LY, et al. Acta Pharmacol Sin. 2022 Jun;43(6):1534-1543. doi: 10.1038/s41401-021-00774-6. Epub 2021 Sep 22. Acta Pharmacol Sin. 2022. PMID: 34552215 Free PMC article. - Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management.
Belum VR, Cercek A, Sanz-Motilva V, Lacouture ME. Belum VR, et al. Curr Treat Options Oncol. 2013 Sep;14(3):389-404. doi: 10.1007/s11864-013-0254-4. Curr Treat Options Oncol. 2013. PMID: 23996476 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials